Vizora日本語

Kubota Pharmaceutical HoldingsKubota Pharmaceutical Holdings Co., Ltd.4596東証グロース医薬品FY ending Dec 2023, consolidated, IFRS

Kubota Pharmaceutical Holdings FY ending Dec 2020 results

Kubota Pharmaceutical Holdings brought in ¥37.8M in revenue.

It lost about ¥6574 for every ¥100 of sales at the operating level.

Revenue changed -95.5% from the prior year.

What changed from last year

FY ending Dec 2016 → FY ending Dec 2020

Revenue
-95.5%¥846.3M → ¥37.8M
Net income attributable to owners
Loss-¥3.91B → -¥2.44B
Operating cash flow
Loss-¥3.2B → -¥2.25B

Where the money goes

FY ending Dec 2016 → FY ending Dec 2020

※ Cost of revenue is not disclosed; expenses are combined

Where ¥100 of sales goes

For every ¥100 Kubota Pharmaceutical Holdings sells, how much goes where, and how much is kept.

FY ending Dec 2020
Operating costs
¥6674
Operating loss
¥6574
Net loss
¥6451

Annual margin trends

Operating margin-6574.0%
FY ending Dec 2020: -6574.0%-6574.0%FY16FY20
Net margin-6450.6%
FY ending Dec 2016: -462.1%-462.1%FY ending Dec 2020: -6450.6%-6450.6%FY16FY20

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Sources

Show source documents (4)

  • EDINET (FSA Japan)

    有価証券報告書－第10期(2024/01/01－2024/12/31)

    ID S100VISG2025-03-28Open

  • EDINET (FSA Japan)

    有価証券報告書－第8期(2022/01/01－2022/12/31)

    ID S100QHRB2023-03-29Open

  • EDINET (FSA Japan)

    有価証券報告書－第7期(令和3年1月1日－令和3年12月31日)

    ID S100NRX42022-03-29Open

  • EDINET (FSA Japan)

    有価証券報告書－第6期(令和2年1月1日－令和2年12月31日)

    ID S100L2EY2021-03-29Open

Extracted from XBRL: 32 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open MarkdownShare on XSave image